View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 24, 2021updated 11 Jul 2022 2:17pm

AstraZeneca and Hutchmed start lung cancer therapy trial in China 

The primary goal of the trial will be median progression-free survival as measured by investigators.

AstraZeneca and Hutchmed have commenced the Phase III SACHI clinical trial of Orpathys (savolitinib), plus Tagrisso (osimertinib) in locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC) patients in China.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The first subject in the trial was administered the first dose, Hutchmed noted.

Savolitinib is an oral and selective MET tyrosine kinase inhibitor (TKI), marketed as Orpathys in China.

It works by hindering the MET receptor tyrosine kinase pathway activation that is caused by gene amplification or mutations.

The companies had signed an international licensing agreement in 2011 to co-develop and co-market savolitinib.

Hutchmed is carrying out the development activities in China while AstraZeneca oversees the development outside of the country.

An irreversible epidermal growth factor receptor (EGFR) TKI, AstraZeneca’s Tagrisso is claimed to offer clinical activity against central nervous system metastases.

The open-label, multicentre, randomised, controlled trial will assess the efficacy and safety of Orpathys plus Tagrisso versus platinum-based doublet-chemotherapy in patients who have developed MET amplification after disease progression on EGFR inhibitor treatment.

Median progression-free survival (PFS) as measured by trial investigators will be the primary goal.

Median PFS evaluated by an independent review committee, objective response rate, median overall survival, duration of response, time to response, disease control rate and safety will be included as other goals.

The SACHI study builds on positive data from the Phase Ib/II TATTON trial of the combination therapy in more than 220 individuals with EGFR inhibitor refractory NSCLC whose tumours harbour aberrations of MET.

Data showed that Orpathys plus Tagrisso had good anti-tumour activity, as well as a favourable risk-benefit profile.

Earlier this month, the companies started a Phase III SAMETA trial of savolitinib, plus Imfinzi (durvalumab) to treat advanced papillary renal cell carcinoma patients.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena